340 CORE TEMPERATURE OF END-STAGE OSTEOARTHRITIC KNEE  by Ota, M. et al.
S180 Poster Presentations
338
INVESTIGATIONS OF INTER- AND INTRA-INDIVIDUAL
RELATIONSHIPS BETWEEN ABSORPTION OF ORAL
SALMON CALCITONIN AND A SURROGATE MARKER OF
PHARMACODYNAMIC EFFICACY
M.A. Karsdal, I. Byrjalsen, K. Henriksen, B.J. Riis,
C. Christiansen
Nordic BioSci. A/S, Herlev, Denmark
Purpose: The aim of the study was to compare inter- and intra-
individual bioavailability of 0.8 mg of oral salmon calcitonin (sCT)
given once before or after food intake to assess the relationship
between bioavailability and levels of the bone resorption biomarker,
serum C-terminal telopeptide of collagen type I (CTX-I).
Methods: Participants were from two randomized, double-blind,
placebo-controlled studies. Study I was a cross-over trial including
healthy postmenopausal women receiving a single dose of 0.8
mg of oral sCT or placebo pre-breakfast at 08:00 (n=42), pre-
dinner at 17:00 (n=20), or post-dinner at 22:00 (n=19). Blood
samples were taken before drug intake, and at 5, 10, 15, 30, 45
minutes, 1, 1½, 2, 2½, 3 hours, and every subsequent hour until
24 hours after dosing. Study II investigated the pharmacokinetics
and pharmacodynamics of oral sCT administered on days 1 and
14 to postmenopausal women and men (n=73) suffering from
osteoarthritis (OA). In one treatment arm, 0.8 mg of oral sCT was
given twice daily with one dose in the morning at 08:00 and one
dose given pre-dinner at 17:00 (n=26). On treatment day 1 and
day 14, blood samples were taken before drug intake, and at 10,
15, 30, 45 minutes, and 1, 2, and 4 hours post-dose. In both
studies the absorption of calcitonin was assessed by plasma sCT
concentrations, and bone resorption by the biochemical marker of
serum CTX-I.
Results: Irrespective of dosing time, a single dose of 0.8 mg
oral sCT was rapidly absorbed, reaching Cmax between 15 to 30
minutes in both low and high absorbers. Following Cmax, sCT
was eliminated from plasma with a half-life between 9 and 15
minutes. Overall, a single dose of 0.8 mg oral sCT resulted in
signiﬁcant suppression of serum CTX-I compared with placebo
irrespective of the level of absorption of sCT. At all three dosing
times a signiﬁcantly higher suppression of sCTX-I was observed in
subjects with the highest intestinal absorption of sCT. The effect of
increased absorption of sCT was a marked prolongation of serum
CTX-1 suppression whereas acute suppression 1 to 2 hours after
dosing was unaffected. A high degree of correlation between the
level of absorption of sCT and the suppression of serum CTX-I
was observed at all three dosing times, i.e. a Pearson correlation
coefﬁcient of r = -0.74, r = -0.94, and r = -0.78, was found at
the dose times 08:00, 17:00, and 22:00. A weak association of
borderline signiﬁcance was found in the intra-individual absorption
of sCT on dosing days 1 and 14 with r = 0.40 and r = 0.38 at
the dose times 08:00 and 17:00. As expected, the intra-individual
response in serum CTX-I levels was statistically non-signiﬁcantly
associated on dosing days 1 and 14 with r = 0.34 and r = 0.27 at
the dose times 08:00 and 17:00.
Conclusions: Increased bioavailability of orally administered 0.8
mg sCT is highly correlated with suppression of the bone resorp-
tion marker, serum CTX-I. Moreover, the effect is highly controlled
with a minimum of individual variability in serum CTX-I. The
variable absorption of the drug demonstrates the importance of
determining the optimal conditions for ensuring a most beneﬁcial
drug uptake.
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EXTRACORPOREAL SHOCKWAVE SHOWS
REGENERATION IN HIP NECROSIS
C.-J. Wang
Chang Gung Mem. Hosp. -Kaohsiung Med. Ctr., Chang Gung
Univ. Coll. of Med., Taiwan, Kaohsiung Hsien, Taiwan
Purpose: The effect of shockwave in osteonecrosis of the femoral
head (ONFH) is poorly understood. The purpose of this study was
to investigate the regeneration effects of shockwave in ONFH.
Methods: This study consisted of 14 femoral heads from 14 pa-
tients undergoing total hip arthroplasty for ONFH. Seven patients
with seven hips who received shockwave prior to surgery were
designated as the study group, whereas, seven patients with seven
hips who did not receive shockwave were assigned to the control
group. Both groups showed similar demographic characteristics.
The femoral heads were investigated with histopathological ex-
amination and immunohistochemical analysis with von Willebrand
factor (vWF), VEGF, platelet endothelial cell adhesion molecule-1
(PECAM-1) also referred to as (CD 31) and vascular cell adhesion
molecule (VCAM) for angiogenesis, and with proliferation cell nu-
clear antigen (PCNA), Dickkopf-1 (DKK1) and Winless 3a (Wnt 3)
for bone remodelling and regeneration.
Results: In histopathological examination, the study group showed
signiﬁcantly more viable bone and less necrotic bone, higher
cell concentration and more cell activities including phagocy-
tosis than the control group. In immunohistochemical analysis,
the study group showed signiﬁcant increases in vWF (P<0.01),
VEGF (P<0.0012) and CD 31 (P<0.0023), Wnt3 (P<0.008) and
PCNA (P<0.0011), and decreases in VCAM (P<0.0013) and
DKK1 (P<0.0007) than the control group.
Conclusions: Shockwave treatment signiﬁcantly promotes angio-
genesis and bone remodelling than the control. It appears that
application of shockwave results in regeneration effects in hips
with ONFH.
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CORE TEMPERATURE OF END-STAGE OSTEOARTHRITIC
KNEE
M. Ota1, T. Sasho1, K. Nakagawa1, H. Tsuruoka1, S. Sato1,
S. Maki1, K. Takahashi1, T. Lee2, C. Shirai2
1chiba Univ., Chiba, Japan; 2chiba rehabilitation center, Chiba,
Japan
Purpose: Knee osteoarthritis (KOA) is one of the commonest
joint diseases in an aged society. Among several complaints
patients have, knee pain is most bothering to the patients. But the
mechanisms concerning knee pain are poorly understood. Certain
researchers refer to blood ﬂow disturbance of the subchondral
bone in KOA as possible cause of knee pain. Up until now, several
studies have been performed about blood ﬂow of bone marrow
in femur and tibia, and controversial results have been reported.
In the present study, we measured the core temperature of OA
knees which is considered to reﬂect blood ﬂow of deep structures.
Methods: End-stage KOA patients who were hospitalized and
were waiting for total knee althroplasty (TKA) were involved in this
study (n=16). As a control knees, healthy volunteers who had not
had any knee symptoms were selected (n=10). Measurement of
the core temperature of knee joint as well as sternum area was
performed using Core-temp CM-210 (Terumo, Tokyo). With this
apparatus core temperature was measured by simply attaching
small metal probe to skin surface. (Zero-heat-ﬂow method) Core
temperatures of both groups of knees were monitored over night
on ten-minute basis and compared. Moreover end-stage patients
were divided into two groups: i.e.; those with night pain (N-group)
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and those without night pain (WN-group) and core temperature
of theirs was compared. Statistical analysis was performed using
repeated measures ANOVA and p value less than 0.05 was
considered as statistically signiﬁcant.
Results: Core temperature of both the knee and the sternum
decreased at around 5 am according to circadian rhythm.
Core temperature of the knee was signiﬁcantly lower than that of
the sternum in KOA. On the other hand, such difference was not
seen in control knees.
Core temperature of the knee between N-group and WN-group
was not different.
Conclusions: We revealed the lower core temperature of the
knee in end-stage KOA. This indicated existence of blood ﬂow
disturbance in OA knees. Our data supports decreased bone
perfusion in KOA exhibited with perfusion MRI. Elevated bone
marrow pressure measured with invasive technique was also
reported as one possible mechanisms of KOA pain and it might
related to blood ﬂow disturbance, though inconsistent results was
reported about bone marrow pressure.
In the present study, we ﬁrstly reported blood ﬂow disturbance in
KOA by measuring core temperature. We only dealt end-stage OA
patients in this study, but this non-invasive method might be useful
in monitoring KOA status.
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DURATION OF A SINGLE INTRAARTICULAR INJECTION OF
GEL-200 AND SAFETY OF RE-TREATMENT OF GEL-200, A
NEW CROSS-LINKED FORMULATION OF HYALURONIC
ACID [HA] IN THE TREATMENT OF SYMPTOMATIC
OSTEOARTHRITIS [OA] OF THE KNEE
H.S. Baraf1, V. Strand2, H. Hosokawa3, O. Akahane3, S. Lim3,
M. Yaguchi3
1The Ctr. For Rheumatology and Bone Res., Wheaton, MD; 2Div.
of Immunology/Rheumatology, Stanford Univ., Palo Alto, CA;
3Seikagaku Corp., Tokyo, Japan
Purpose: This was a randomized controlled trial (RCT) with exten-
sion and open-label re-treatment phases to determine if single or
repeated intra-articular injections of Gel-200 are safe and effective
in subjects with symptomatic knee osteoarthritis.
Methods: Subjects completing Week 13 in SI-6606/01 RCT were
offered enrollment in extension phase, evaluating durability of
responses relative to initial baseline for up to 13 weeks. If and
when subjects qualiﬁed for re-treatment based on WOMAC pain
subscore ≥40 mm in treated knee, they received a single injection
of Gel-200 at Week R0 (open-label baseline). Survival analyses
were conducted in Kaplan-Meier and Cox proportional hazard
models to compare time to re-treatment eligibility using 2 different
pre-speciﬁed endpoints: (A) WOMAC pain subscore ≥40 mm; and
(B) WOMAC Pain ≥40 mm and improvement from baseline <20
mm.
Results: Of 350 completing SI-6606/01; 258 subjects entered
extension: 199 subjects were re-treated with Gel-200; 74 ana-
lyzed for continued effectiveness. Kaplan-Meier estimates showed
a statistically signiﬁcant advantage for Gel-200 in both Endpoints
A (p=0.049) and B (p=0.034). [Table] Median times to re-treatment
eligibility were 6.3 weeks for subjects initially receiving Gel-200
compared with 3.7 weeks for PBS by (A), and 13.1 vs 6.0 weeks by
Endpoint (B). In Cox proportional hazard models, Gel-200 showed
statistically signiﬁcant advantages in durability of response, using
treatment, age, and baseline WOMAC pain subscore as covariates
for Endpoints A (p=0.019) and B (p=0.027). All subjects receiv-
ing open label Gel-200 demonstrated improvement from Week
R0 baseline in WOMAC scores (pain, stiffness, function, total),
global assessments (subject, physician) (P<0.0001); incidence of
adverse events [AEs] within 24 hours of injection were comparable
to those observed in initial RCT. There were no allergic reactions
or unanticipated device-related AE. Serious AE occurred in 6
subjects, none related to the study injection.
Survival Analysis - Kaplan-Meier Estimates
Weeks post injection Endpoint A Endpoint B
in the SI-6606/01 study (p=0.049) (p=0.034)
Gel-200 PBS Gel-200 PBS
(N=247) (N=128) (N=247) (N=128)
Week 1 1.000 1.000 1.000 1.000
Week 3 0.952 0.941 0.961 0.942
Week 6 0.522 0.390 0.616 0.500
Week 9 0.473 0.355 0.560 0.441
Week 13 0.419 0.346 0.514 0.406
Week 16 (Week 3 in Extension phase) 0.292 0.264 0.387 0.342
Week 19 (Week 6 in Extension phase) 0.292 0.264 0.387 0.342
Week 22 (Week 9 in Extension phase) 0.280 0.264 0.375 0.342
Week 26 (Week 13 in Extension phase) 0.280 0.237 0.375 0.317
Conclusions: Together, these data support the efﬁcacy and dura-
bility of response of a single intraarticular injection of Gel-200 over
13 weeks as treatment for knee osteoarthritis. This study also
demonstrated that repeat treatment of Gel-200 was well tolerated.
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DOSE STABILITY OF TAPENTADOL EXTENDED RELEASE
AND OXYCODONE CONTROLLED RELEASE IN A
ONE-YEAR, RANDOMIZED, OPEN-LABEL, PHASE 3
SAFETY TRIAL IN PATIENTS WITH CHRONIC LOW BACK
OR OSTEOARTHRITIS PAIN
S. Grond1, B. Kuperwasser2, B. McCann2, M. Etropolski2,
R. Lange3, B. Lange3, A. Okamoto2, J. Gilbert4, A. Steup3,
C. Rauschkolb2
1Univ. Klinik für Anästhesiologie und Operative Intensivmedizin,
Martin-Luther-Univ., Halle, Germany; 2Johnson & Johnson
Pharmaceutical Res. & Dev., L.L.C., Raritan, NJ; 3Res. and Dev.,
Grünenthal GmbH, Aachen, Germany; 4Johnson & Johnson
Pharmaceutical Res. & Dev., Div. of Janssen-Cilag Ltd., High
Wycombe, United Kingdom
Purpose: To assess the long-term safety and effectiveness of
tapentadol extended release (ER), a novel centrally acting anal-
gesic in development for the management of moderate to severe
chronic pain, over 1 year of treatment in patients with chronic low
back or osteoarthritis pain.
Methods: Patients were randomized 4:1 to receive controlled,
adjustable, oral bid doses of tapentadol ER 100-250 mg or oxy-
codone HCl controlled release (CR) 20-50 mg. In order to establish
an optimal therapeutic dose, deﬁned as a dose providing a bal-
ance of efﬁcacy and tolerability, patients could titrate their doses in
increments of 50-mg bid tapentadol ER or 10-mg bid oxycodone
HCl CR during a 51-week maintenance period. Safety was as-
sessed for all patients who received at least 1 dose of study
medication.
Results: Patients received tapentadol ER (n = 894) or oxycodone
CR (n = 224). The mean (standard deviation) and median most
frequently used daily doses were 352.2 (132.43) mg and 400
mg with tapentadol ER and 56.8 (30.07) mg and 40 mg with
oxycodone HCl CR. Patients who received tapentadol ER and
oxycodone CR took the most frequently used dose for a median
duration of 133.5 and 45.0 consecutive days, respectively. Patients
in the oxycodone CR group discontinued treatment earlier than
patients in the tapentadol ER group; in the ﬁrst 4 weeks of
the study, approximately 40% of patients in the oxycodone CR
group discontinued treatment compared with approximately 20%
of patients in the tapentadol ER group. The percentage of patients
who discontinued because of adverse events (AEs) during the
